Boom for Prostate Cancer Drugs?

Wednesday, 01 February 2012 04:48 PM

The prostate cancer drug market is heading toward boom times, according to new predictions by two leading business publications.
Barron’s and the Wall Street Journal are both reporting the market for new drugs that treat advanced cases of prostate cancer -- a leading cause of death in men -- is projected to surge by the end of the decade. Barron's predicts the market could rise from approximately $1 billion to $8 billion in that time.
“We count at least 10 late-stage trial results due for release within the next four years and believe that the potential success of any one particular therapeutic cannot be analyzed in isolation,” Barron’s reported, in an analysis of new drugs headed to market.
Among the next-generation products: Medivation's MDV3100; Algeta's Alpharadin; Exelixis' cabozantinib; Dendreon's Provenge; Johnson & Johnson's Zytiga; and Amgen's Xgeva.
If true, the market surge would contrast with years of frustrating results on new prostate cancer treatments, according to the Journal. The pharmaceutical industry has turned out just five new treatments for advanced prostate cancer in three years.

© HealthDay

1Like our page
The market for drugs that treat advanced prostate cancer is expected to surge over the next decade, experts predict.
Wednesday, 01 February 2012 04:48 PM
Newsmax Media, Inc.

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved